載入中
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
前收盤價
US$40.07
−US$0.16 · -0.40%
盤前
US$40.37
+US$0.30 · +0.75%
10月12日 上午4:08 ET
盤中時間採用ET。市場資料可能有所延遲。
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
日內區間
目前US$40.07
52週區間
目前US$40.07
盤中時間採用ET。市場資料可能有所延遲。
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
日內區間
目前US$40.07
52週區間
目前US$40.07
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（EUR） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 467.16億 EUR | 442.86億 EUR | 416.18億 EUR | 405.61億 EUR | 391.75億 EUR |
| 銷貨成本 | 130.49億 EUR | 132.05億 EUR | 126.28億 EUR | 118.82億 EUR | 122.55億 EUR |
| 毛利 | 336.67億 EUR | 310.81億 EUR | 289.9億 EUR | 286.79億 EUR | 269.2億 EUR |
| 研究與開發 | 78.42億 EUR | 73.94億 EUR | 65.07億 EUR | 65.01億 EUR | 56.92億 EUR |
| 銷售、一般及管理費用 | 102.42億 EUR | 91.83億 EUR | 89.33億 EUR | 87.39億 EUR | 95.55億 EUR |
| 營業費用 | 240.7億 EUR | 238.29億 EUR | 220.3億 EUR | 185.17億 EUR | 187.94億 EUR |
| 利息收入 | 3.31億 EUR | 4.58億 EUR | 5.31億 EUR | 1.69億 EUR | 312.7萬 EUR |
| 利息支出 | 6.26億 EUR | 6.23億 EUR | 5.13億 EUR | 3.85億 EUR | 3.77億 EUR |
| 折舊和攤銷 | 56.78億 EUR | 35.86億 EUR | 44.29億 EUR | 31.08億 EUR | 33.51億 EUR |
| 營業利益 | 95.97億 EUR | 72.52億 EUR | 69.6億 EUR | 101.62億 EUR | 81.26億 EUR |
| 淨利 | 78.13億 EUR | 55.6億 EUR | 54億 EUR | 83.71億 EUR | 62.23億 EUR |
公司資料更新於 2026年10月12日。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$49.50
上漲空間 23.53%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2013年9月30日 | 5:1 | — | — |
股票分割 | 2010年11月17日 | 10:1 | — | — |
已生效 2013年9月30日
5:1
已生效 2010年11月17日
10:1
報告持有此股票曝險的交易所交易基金。
Avantis International Equity ETFAVDE4100.19萬0.21%192.24億 USD0.23%US$89.80+0.58%
Fidelity Enhanced International ETFFENI3581.03萬0.31%114.7億 USD0.28%US$39.69+0.43%
VanEck Pharmaceutical ETFPPH3353.54萬3.27%10.37億 USD0.36%US$110.49+1.20%
First Trust Value Line Dividend Index FundFVD3033.03萬0.40%76.22億 USD0.62%US$47.66+0.13%
Invesco International Dividend Achievers ETFPID2496.01萬2.91%8.58億 USD0.53%US$21.7117+0.10%
Portfolio Building Block World Pharma and Biotech Index ETFPBPH1922.54萬1.87%10.27億 USD0.13%US$28.3551+1.40%
GMO International Value ETFGMOI1658.39萬2.50%6.54億 USD0.60%US$39.18+0.26%
Brown Advisory Sustainable Value ETFBASV603.96萬1.46%4.14億 USD0.71%US$30.5406+0.54%Avantis International Equity ETFAVDEFidelity Enhanced International ETFFENIVanEck Pharmaceutical ETFPPHFirst Trust Value Line Dividend Index FundFVDInvesco International Dividend Achievers ETFPIDPortfolio Building Block World Pharma and Biotech Index ETFPBPHGMO International Value ETFGMOIBrown Advisory Sustainable Value ETFBASVAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
